Health-care companies slipped as a bias for high-risk sectors offset a boost from deal activity. Vertex Pharmaceuticals agreed to acquire Alpine Immune Sciences for $4.9 billion in cash,.
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here.
A coronary sinus reducer met one of two primary endpoints by reducing refractory angina in the ORBITA-COSMIC trial, but not the second, improvement in perfusion.
The Nashville Ledger tnledger.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tnledger.com Daily Mail and Mail on Sunday newspapers.